CITIIQ
27.8.2020 12:32:13 CEST | Business Wire | Press release
CitiIQ (http://www.citiiq.com ) has applied its novel measurement standard to 1,170 global cities as an important step toward measuring the 4,000 cities of the world with a population over 100,000.
The 1,170 cities include those with populations greater than 500,000, the world’s country capitals, and the state capitals of Brazil, India China and the USA.
“Increasingly, the health and wellbeing of people depend upon the effectiveness of their city,” says Don Simmonds, Chief Executive Officer of CitiIQ. “Municipal leaders face immense challenges and benefit greatly when comprehensive, comparable data is available to guide their decisions.”
Most cities struggle to translate disparate data into actions that can make life better for their citizens. The CitiIQ measurement system is an objective assessment of the overall health and wellbeing of a city. It converts raw data into scores out of 100 so that city elements are readily compared within a given city, or with other cities around the world.
CitiIQ uses an evidence-based methodology to score 35 essential elements, or Considerations, within five prioritized Dimensions including Basic Needs, Competitiveness, Opportunity, Livability, and Destiny. Using an intuitive online dashboard, a city’s measurements are readily available to clients through a cloud-based annual subscription.
“The CitiIQ measurement helps immensely in understanding the factors that influence a city,” says Harry Loubser, Managing Director of Unashamedly Ethical based in Cape Town, South Africa. “It's value to municipal leaders is readily apparent but the ability to compare city to city across so much of the world is a powerful advantage. We can clearly identify where best practise has been applied, but also illuminate cities with the greatest needs.”
The CitiIQ system is easy to use, economical, and effective with no need to purchase new software or abandon existing metrics. Aligned with the United Nations Sustainable Development Goals, CitiIQ provides a practical way for a city to mark progress toward SDG achievement.
City Administrators appreciate the integration of economic, environmental, social and cultural infrastructure measures reflecting how a city actually functions. The algorithm normalizes data into a comparable, holistic picture of their city’s strengths and weaknesses bringing coherence and comparability to their operations and an ability to compare with other cities.
In April 2020 CitiIQ was selected by UN-Habitat to develop a COVID-19 Readiness and Responsiveness tracking site for more than 1,000 global cities. Data was often unavailable at a city level where the real battle is fought. The scoring reflects both how ready a city was for COVID-19 and how well they are responding to the pandemic. COVID-19 data is collected daily for the 1,000 cities supporting improve responses to the pandemic. Visit: https://unhabitat.citiiq.com/ .
About CitiIQ
CitiIQ is a comprehensive system that objectively measures the overall health and wellbeing of a city. Using an intuitive online dashboard style interface, a city’s measurements are made readily available to clients through a cloud-based annual subscription.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom